[目的]研究ER、PR和Ki67在卵巢上皮性癌中的表达及其临床意义。[方法]用单克隆抗体、免疫组化技术测定74例原发性卵巢上皮性癌患者中ER、PR和Ki67的表达。[结果]ER、PR、Ki67的阳性表达率分别是59.5%、60.8%、74.3%,PR表达与临床分期相关。多因素分析显示PR表达、临床分期是独立的预后因素。[结论]在卵巢上皮性癌中,PR表达、临床分期具有独立的判断患者预后的价值。 [Objective] To investigate the expression and clinical significance of ER, PR and Ki67 in epithelial ovarian cancer. [Method] The expression of ER, PR and Ki67 in 74 patients with primary epithelial ovarian cancer were detected by monoclonal antibody and immunohistochemistry. [Results] The positive rates of ER, PR and Ki67 were 59.5%, 60.8% and 74.3%, respectively. The expression of PR correlated with clinical stage. Multivariate analysis showed that PR expression and clinical stage were independent prognostic factors. [Conclusion] In ovarian epithelial carcinoma, PR expression and clinical stage have the independent value of judging the prognosis of patients.